Streetbeat News

Stock Prices

LULU

Truist Securities analyst Scot Ciccarelli has reaffirmed a Buy rating on Lululemon Athletica (NASDAQ:LULU) and increased the price target from $555 to $561.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 7:38 pm

WBD

Warner Bros Discovery Inc's (NASDAQ:WBD) 'Hogwarts Legacy' has sold 22 million copies in 2023, potentially becoming the best-selling game of the year. The game's success is notable as it may be the first time since 2009 that neither a Call of Duty nor a Rockstar game has topped the annual sales chart. Warner Bros. Interactive Entertainment is exploring further Harry Potter-themed projects, including a Quidditch game.

Portfolio Pulse from Franca Quarneti

January 09, 2024 | 7:37 pm

SIX

Truist Securities analyst Michael Swartz has maintained a Hold rating on Six Flags Entertainment (NYSE:SIX) and increased the price target from $23 to $24.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 7:27 pm

SEAS

Truist Securities analyst Michael Swartz has maintained a Buy rating on SeaWorld Entertainment (NYSE:SEAS) and increased the price target from $58 to $60.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 7:25 pm

ONEW

Truist Securities analyst Michael Swartz has reaffirmed a Buy rating on OneWater Marine (NASDAQ:ONEW) and increased the price target from $30 to $38, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 7:20 pm

CDW

CDW Corporation (NYSE:CDW) has experienced a 39.31% increase in short interest since its last report, with 2.38 million shares sold short, representing 2.02% of its float. The average time to cover these short positions is 1.46 days. While an increase in short interest can indicate bearish sentiment, CDW's short interest is below its peer group average of 4.06%. This information suggests investor caution but does not necessarily predict a price drop.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 7:15 pm

NOC

Northrop Grumman (NYSE:NOC) has seen a 6.8% increase in short interest since the last report, with 1.65 million shares sold short, representing 1.1% of available shares. The short interest is lower than the peer group average of 3.06%. While an increase in short interest can indicate bearish sentiment, it does not necessarily predict a near-term price drop.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 7:15 pm

DHI

D.R. Horton (NYSE:DHI) has seen a 28.53% decrease in short interest since the last report, with 6.70 million shares sold short, representing 2.53% of available shares. The average time to cover these short positions is 1.8 days. A decrease in short interest can indicate a more bullish sentiment towards the stock. D.R. Horton's short interest is below its peer group average of 6.43%. While a decline in short interest does not necessarily predict a stock price increase, it suggests fewer traders are betting against the stock.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 7:15 pm

AMD

HPE

JNPR

NVDA

SRPT

U

On Tuesday, Wall Street saw mixed performance with the Nasdaq 100 slightly up and the S&P 500 and Dow Jones down ahead of inflation data and earnings season. Nvidia (NVDA) hit a record high, while Advanced Micro Devices (AMD) also gained. The SPDR S&P 500 ETF (SPY), SPDR Dow Jones ETF (DIA), and Invesco QQQ Trust (QQQ) showed varied movements. Juniper Networks (JNPR) surged on acquisition news by Hewlett Packard Enterprise (HPE), which fell in response. Sarepta Therapeutics (SRPT) continued its rise, and Unity Software (U) dropped after announcing job cuts.

Portfolio Pulse from Piero Cingari

January 09, 2024 | 7:14 pm

BNTX

PFE

BioNTech SE (NASDAQ:BNTX) announced at the J.P. Morgan Healthcare Conference that it anticipates revenue growth to resume in 2025, driven by oncology and respiratory vaccine launches, pending successful development and regulatory approval. The company forecasts a decrease in total revenue to €3 billion in FY24, down from €4 billion in 2023. BioNTech plans to initiate ten or more late-stage cancer drug trials by the end of 2024 and expects to launch its first oncology drugs from 2026. CEO Ugur Sahin highlighted the expansion of their oncology pipeline and the company's strong financial position with €17.5 billion in cash and investments at the end of 2023. BNTX shares dropped 3.17% to $108.33.

Portfolio Pulse from Vandana Singh

January 09, 2024 | 7:11 pm